MicroGenesys' VaxSyn HIV-1

Executive Summary

Wyeth-Ayerst plans to terminate its relationship with Meriden, Conn.-based firm for the development of the company's gp 160 AIDS therapeutic vaccine, Wyeth-Ayerst reports Jan. 14. Commenting on the end of an R&D collaboration that has existed since 1990, Wyeth-Ayerst research president Robert Levy, MD, said: "We have agreed to unwind our involvement with this project on amicable terms." A Phase III trial of VaxSyn HIV-1 that was scheduled to utilize a $20 mil. congressional appropriation to DoD was postponed for review by FDA and NIH until April 1994. MicroGeneSys had hoped to have patients receiving vaccine by early 1994...